Neoplasms Clinical Trial
Official title:
The Effects of a 6-week Balance, Agility, Strengthening Exercise (BASE) Class on Balance Performance, Self-Efficacy, and Fear of Falling in Cancer Survivors
Cancer treatments can have a significant impact on a cancer survivor's function and independence, and these patients can have twice the incidence of falls than their cancer-free peers. Balance programs of varying lengths have shown to improve balance performance, increase self-efficacy and decrease fear of falling; however, there are limited intervention studies amongst cancer survivors, and none that examine the combination of balance performance, self-efficacy and fear of falling. It is believed that this study will show that a 6-week Balance, Agility, Strengthening Exercise (BASE) Class is a sufficient time frame to demonstrate a positive effect on balance performance, self-efficacy, and fear of failing in cancer survivors, and will add to the body of knowledge in this population.
Objectives Given that this combination of outcomes have not been sufficiently measured in the
cancer population, and most balance and agility training programs are 12 weeks or more in
length, the objectives of this study is to determine the effects of a 6-week intervention,
the Balance, Agility, Strengthening Exercise (BASE) Class, on the balance performance,
self-efficacy, and the fear of falling in cancer survivors.
Methods This study is a 3 year exercise interventional study, with 20 participants per year.
In year one of the study, 20 participants will be enrolled in a 6-week Balance, Agility,
Strengthening Exercise (BASE) Class. The pre-program data collection will include:
demographic data; initial intake examination utilizing standard physiotherapy assessment of
range of motion, flexibility, and strength; use of validated balance performance tools; and
validated self-report surveys for balance confidence, fear of falling, and quality of life.
The participants will attend the BASE class twice weekly for 6-weeks. The post-program data
collection is to include the same outcome measures.
Subsequent years will be an observational study of the same design, enrolling 20 participants
in year 2 and 3 for a 6-week BASE class. A total of 60 participants will be recruited over 3
years providing adequate power to assess program efficacy. Based on the resources available,
this study can only accommodate 20 participants per year and can only be conducted for a
6-week period each year of the study.
Participants and recruitment Posters and hand bills will be distributed and placed throughout
CancerCare recruiting participants for the study (self-referral). In addition, hand bills
will provided for oncologists, oncology nurses, and psychosocial clinicians to give to
patients/potential participants within the clinical areas at CancerCare. After receiving the
hand bill with the study description and information, potential participants can choose to
phone or e-mail the PI to indicate their interest in the study. A phone interaction will take
place between the PI and potential participant to determine if they meet the inclusion
criteria. Once it is determined that they meet the inclusion criteria, an in-person meeting
will be arranged and they will be provided with the study's objectives, risks and benefits,
and the consent document. Time will be allowed for the potential participant to ask questions
and to consider their enrollment in the study. After a thorough discussion and review of the
documents, the potential participant will be asked to sign the consent form. If requested, a
person will be allowed to take the consent form home for further consideration prior to
signing.
Data collection Prior to the start of the BASE Class, an initial assessment will take place.
This assessment will utilize standard physiotherapy assessment of range of motion,
flexibility, and strength; use of validated balance performance tools; and validated
self-report surveys for balance confidence, fear of falling, and quality of life.
Intervention:
The BASE class will run twice weekly for 1.5 hours each session over a 6-week period and will
include a 10-minute warm-up, 30 minutes of static and dynamic balance exercises, 20 minutes
of lower extremity strengthening exercises, and a 10-minute cool-down. There will be weekly
falls prevention and mobility enhancement education provided during the class.
Statistical Analysis Pre-post paired comparisons will be conducted for each balance
performance and self-reported questionnaire measure. A paired T-test or Wilcoxon signed ranks
test will be performed according to the observed distributions.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
| Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
| Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
| Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
| Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
| Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
| Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
| Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
| Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
| Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
| Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
| Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
| Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
| Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
| Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
| Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
| Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A |